Research programme: recombinant human kallikrein 1 - SinobiomedAlternative Names: rhK1
Latest Information Update: 26 Jan 2011
At a glance
- Originator Shanghai Wanxing Bio-Pharmaceutical; Sinobiomed
- Class Enzymes; Recombinant proteins
- Mechanism of Action Kallikrein 1 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Peripheral vascular disorders; Stroke; Thrombosis